Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of Imsidolimab (ANB019) in adults with palmoplantar pustulosis has completed, with results posted on 2022-05-31…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmoplantar Pustulosis

Drugs mentioned

• Imsidolimab (imsidolimab)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Palmoplantar Pustulosis | Phase 2 | Status: COMPLETED | Results posted: 2022-05-31